Real Money authors - Bret Jensen

Bret Jensen

Bret Jensen was chief investment strategist from 2008-2011 for Simplified Asset Management (S.A.M.), a small long/short hedge fund based in Miami. The fund was in top 5% of long/short hedge funds for total return in its first full year (2009) as ranked by Hedgeco fund database (more than 450 funds in category). Jensen has nearly 20 years of experience in the financial services industry, including more than a decade of managerial experience at American Express. He holds a Bachelor of Science degree in finance from Arizona State University. His personal blog is at Jensen acts as corporate secretary for Florida Alternative Investment Association, which encompasses more than 100 managers managing more than $30 billion in assets under management. Follow Bret on Twitter: @Bret_Jensen.
Email Bret Jensen

Recent Articles By The Author

This Trade Might Just Knock Your Socks Off

Here's a 'shorts' idea in famed underwear name Hanes.

Is This Market More Than Overdue for a Pause?

We are probably at or very near the highs the market will provide at least through the first half of year.

Look for More Upside in These 2 Stocks, Even Against a Challenging Backdrop

Both names should see growth in 2023 and they're reasonably valued.

Cash Is King Once Again in This Market Environment

After more than a decade of historically low to near zero interest rates, cash has value again.

Call This Trade a 'LITE' Bulb Moment

Here's a relatively conservative options play in a communications technology company.

I'm Making Small Bets With These 2 Stocks

While I remain cautious on the overall market, I continue to act upon the limited opportunities I'm finding in the current market.

Tea Leaves Point to a Weakening Outlook for Consumers and Economy

The nice start for the market in 2023 will soon fade.

2 Key Real Estate Stocks Suffer as the Florida Migration Accelerates

This huge exodus shows no signs of slowing down any time soon.

This Small Pharma Company Could Develop Into a Nice Trade

Let's see how to trade GlycoMimetics, a clinical-stage drug developer focused on a type of cancer treatment.

Over and Out on a Good Note

It was good to sit on the Daily Diary and have a nice rally in the market happen on my watch. It has been a while. We saw very good momentum in equities in the back half of the trading day as the Nasdaq marches to an over 2.5% gain on this options e...

Email sent

Thank you, your email to has been sent successfully.


We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight